4D Molecular Therapeutics (FDMT) Net Income Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Net Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | 63.48% |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 708.55 Mn | 317.66 Mn | - | -91.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.98% |
| Dec 31, 2025 | 135.65% |
| Sep 30, 2025 | -10.16% |
| Jun 30, 2025 | -97.77% |
| Mar 31, 2025 | -26.57% |
| Dec 31, 2024 | -52.85% |
| Sep 30, 2024 | -168.03% |
| Jun 30, 2024 | 11.36% |
| Mar 31, 2024 | 20.76% |
| Dec 31, 2023 | -9.21% |
| Sep 30, 2023 | 38.54% |
| Jun 30, 2023 | -49.81% |
| Mar 31, 2023 | -48.79% |
| Dec 31, 2022 | -15.25% |
| Sep 30, 2022 | 0.45% |
| Jun 30, 2022 | -217.09% |
| Mar 31, 2022 | 22.89% |
| Dec 31, 2021 | 77.64% |
| Sep 30, 2021 | -508.45% |
| Jun 30, 2021 | 28.68% |